NCT01653158

CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

A Phase 1b Dose Escalation, Open-label Study Of CP-751,871 In Combination With Docetaxel In Advanced Non-hematologic Malignancies

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic malignancies for whom docetaxel is a reasonable treatment option.

Conditions

• Advanced Non-Hematologic Malignancies

Interventions

Type	Name	Description
DRUG	CP-751,871	CP-751,871 was given intravenously \[IV\] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg. Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year).
DRUG	Docetaxel	Docetaxel up to 75 mg/m\^2 was administered intravenously \[IV\] on Day 1 of each 3-week dosing cycle.

Timeline

• Start date: 2005-03-01
• Primary completion: 2009-02-01
• Completion: 2009-02-01
• First posted: 2012-07-30
• Last updated: 2013-10-30
• Results posted: 2013-08-27

Locations

1 site across 1 country: United Kingdom